Market OpportunityRaniPill may be uniquely positioned for the $30B+ GLP-1/obesity space, where size of the patient population makes efficient delivery important for margins and supply chains.
Technology PotentialRani has a potentially transformative technology platform that can turn essentially any drug in the $260B biologics market into an oral, without impacting bioavailability.
ValuationRani is viewed as highly undervalued compared to similar historical drug delivery precedents.